Medication non-compliance is an epidemic that impacts patients, sponsors and the healthcare industry at large, costing the U.S. healthcare system around 300 billion dollars a year. According to a PM360 article that highlights medication compliance in diabetes patient populations, non-adherent patients have inpatient healthcare costs that are 41% higher than those of adherent patients.
Last week on the blog we highlighted BBK’s RSG® Arrive service, which underscores our commitment to patient centricity by easing study visit travel complexities and in turn, expanding clinical research participation. We know that travel can be a hassle, but what if getting a patient to a site could mean the difference between receiving a potentially life-saving treatment or not? What makes a patient travel program such an integral part of the clinical trial landscape?
Imagine a program that takes the hassle out of patient travel within a clinical trial. When dealing with a condition of any sort, be it rare or otherwise, asking a patient to travel across state lines or even to another country, can be a source of anxiety and for many, a financial hardship. Many rare diseases especially, affect newborns who require a parent or guardian to handle travel logistics and accompany the patient. In many instances, travel can affect an entire family not once, but for multiple site visits throughout the course of a study. If not the patients themselves, many parents, guardians or caregivers determine that the complexity involved in getting to a site might outweigh the benefits of participation in a clinical trial. But what if the burden associated with travel could be eliminated?
Topics: Patient Travel